Evidence map›Paper›PMID 21430774›Full record

ArticleNature2011

Catalytic Z-selective olefin cross-metathesis for natural product synthesis.

Simon J Meek, Robert V O'Brien, Josep Llaveria, Richard R Schrock, Amir H Hoveyda

Abstract read
In one paragraph

Article in Nature, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
25.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 399 citations in OpenAlex.

  1. Stereo-reversed E2 unlocksScience (New York, N.Y.) · 2025
    Article
  2. Synthesis of Highly Substituted Alkenes from Terminal Alkynes.Journal of the American Chemical Society · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Accessing Z-Enynes via Cobalt-Catalyzed Propargylic Dehydrogenation.Angewandte Chemie (International ed. in English) · 2024
    Article
  7. Mechanism ofJournal of the American Chemical Society · 2024
    Article
  8. Stereoselective Copper-Catalyzed Olefination of Imines.Angewandte Chemie (International ed. in English) · 2024
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Enantio- andScience advances · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Simon J MeekDepartment of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, Massachusetts 02467, USA.
Robert V O'Brien
Josep Llaveria
Richard R Schrock
Amir H Hoveyda
Boston College · USMassachusetts Institute of Technology · US

Funding

Catalytic Stereoselective Olefin Metathesis ReactionsR01GM059426 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HOVEYDA, AMIR H, SCHROCK, RICHARD R · 2000 to 2019
$10.0M
NIGMS NIH HHS GM-59426NIGMS NIH HHS R01 GM059426
6 · The paper itself

Abstract

Alkenes are found in many biologically active molecules, and there are a large number of chemical transformations in which alkenes act as the reactants or products (or both) of the reaction. Many alkenes exist as either the E or the higher-energy Z stereoisomer. Catalytic procedures for the stereoselective formation of alkenes are valuable, yet methods enabling the synthesis of 1,2-disubstituted Z alkenes are scarce. Here we report catalytic Z-selective cross-metathesis reactions of terminal enol ethers, which have not been reported previously, and of allylic amides, used until now only in E-selective processes. The corresponding disubstituted alkenes are formed in up to >98% Z selectivity and 97% yield. These transformations, promoted by catalysts that contain the highly abundant and inexpensive metal molybdenum, are amenable to gram-scale operations. Use of reduced pressure is introduced as a simple and effective strategy for achieving high stereoselectivity. The utility of this method is demonstrated by its use in syntheses of an anti-oxidant plasmalogen phospholipid, found in electrically active tissues and implicated in Alzheimer's disease, and the potent immunostimulant KRN7000.

Indexed as

Adjuvants, ImmunologicAlkenesAmidesAntioxidantsBiological ProductsCatalysisEthersGalactosylceramidesMolecular StructureMolybdenumPlasmalogensStereoisomerismAdjuvants, ImmunologicAlkenesAmidesAntioxidantsBiological ProductsEthersGalactosylceramidesKRN 7000MolybdenumPlasmalogens

Identifiers

PMID21430774
PMCPMC3082443
OpenAlexW2057117951

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.